Atopic dermatitis (AD) continues to pose challenges for dermatology – not least due to its complex immunopathogenesis [1]. In this interview, Prof. Dr. med. Thomas Kündig, University Hospital Zurich, explains which therapeutic goals are being pursued today, how the different generations of Janus kinase inhibitors (JAKi) differ and which patient groups particularly benefit from JAKi in practice.
You May Also Like
- Case report, molecular basis and therapeutic implications
HER2-positive colorectal carcinoma with invasive micropapillary component
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis
Dyspnea – thoracic lymphoma
- Hemophilia A and B
Personalized approach and innovative treatment options
- Diagnosis and treatment of neurological and psychiatric illnesses
Precision Neurology
- Type 2 diabetes
Pharmacotherapy can lead to remission
- Case Report
Mycosis fungoides in an 11-year-old child
- EHA 2025